Literature DB >> 2541703

The preparation and biochemical characterization of intact capsids of equine infectious anemia virus.

M M Roberts1, S Oroszlan.   

Abstract

Capsids of equine infectious anemia virus have been isolated as cone-shaped particles 60 x 120 nm in size. Detergent treatment of whole virus followed by two cycles of rate-zonal centrifugation in Ficoll produces these capsids in a yield of approximately 10%. The major protein components are the gag-encoded p11 nucleocapsid protein and p26 capsid protein, which are present in equimolar amounts. Substantial cleavage of p11 to p6 and p4 can be observed under conditions where the viral protease packaged in the capsid is enzymatically active.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541703     DOI: 10.1016/0006-291x(89)92459-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.

Authors:  H Jacobsen; L Ahlborn-Laake; R Gugel; J Mous
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.

Authors:  E Priel; S D Showalter; M Roberts; S Oroszlan; D G Blair
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1.

Authors:  R Welker; H Hohenberg; U Tessmer; C Huckhagel; H G Kräusslich
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.

Authors:  C Chen; F Li; R C Montelaro
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein.

Authors:  A Rein; D E Ott; J Mirro; L O Arthur; W Rice; L E Henderson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein.

Authors:  R L Shoeman; B Höner; T J Stoller; C Kesselmeier; M C Miedel; P Traub; M C Graves
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

9.  Determining interdomain structure and dynamics of a retroviral capsid protein in the presence of oligomerization: implication for structural transition in capsid assembly.

Authors:  Kang Chen; Nico Tjandra
Journal:  Biochemistry       Date:  2013-08-01       Impact factor: 3.162

10.  Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication.

Authors:  Charles R Langelier; Virginie Sandrin; Debra M Eckert; Devin E Christensen; Viswanathan Chandrasekaran; Steven L Alam; Christopher Aiken; John C Olsen; Alak Kanti Kar; Joseph G Sodroski; Wesley I Sundquist
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.